Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Xceleron and Organon sign microdose study agreement

12 Sep 2007 - Xceleron Ltd announced a collaboration with Organon, the human healthcare business unit of Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development. Xceleron has been selected by Organon on the basis of fast and cost-effective delivery of human information that will enable them to make better choices in early drug development.
 
The three selected drug candidates are all compounds that have emerged from Organon's gynaecological research and development activities. The purpose of the human microdose study is to quickly assess all important pharmacokinetic properties of the compounds whilst confirming the scalability of the microdose to pharmacological dose for these compounds. Xceleron will use its ultra-sensitive Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.